Malaysia

Health product regulation in Malaysia is administered by two principal bodies under the Ministry of Health (MOH): the National Pharmaceutical Regulatory Agency (NPRA), which governs pharmaceuticals, biologics, and traditional medicines under the Control of Drugs and Cosmetics Regulations 1984 and the Drug Act 1952; and the Medical Device Authority (MDA), which regulates medical devices and in vitro diagnostics under the Medical Device Act 2012 (Act 737). All health products intended for sale or supply in Malaysia must be registered with the relevant authority prior to market entry. The general approval pathway involves submission of a product dossier, conformity assessment, and safety and quality evaluation, followed by issuance of a registration certificate. Pharmaceuticals follow a risk-stratified review process aligned with the ASEAN Common Technical Dossier (ACTD) framework, while medical devices are classified into four risk classes (A through D) with conformity assessment requirements scaling accordingly. Digital health solutions are subject to evolving guidance from the MOH, with classification as medical devices possible where software meets the statutory definition under Act 737.

A local authorized representative or registered agent domiciled in Malaysia is mandatory for all foreign manufacturers seeking product registration with either the NPRA or the MDA. Submissions to the NPRA are accepted in ACTD or ICH Common Technical Document (CTD) format, and reliance pathways referencing approvals from stringent regulatory authorities (SRAs) such as the US FDA, EMA, Health Canada, and TGA Australia are available to expedite review timelines for pharmaceuticals. The MDA accepts technical documentation aligned with ISO 13485 quality management standards and requires evidence of conformity through recognized conformity assessment bodies. Malaysia has undertaken progressive regulatory reforms in recent years, including the operationalization of the MDA's full licensing regime, enhancements to the National Pharmaceutical Regulatory Agency's online submission portal (MeSTI and QUEST3+), and active participation in ASEAN harmonization initiatives through the ASEAN Medical Device Directive (AMDD) and ASEAN Pharmaceutical Product Working Group (PPWG). Post-market surveillance obligations, including mandatory adverse event reporting and periodic safety update requirements, apply to all registered products.

Public sector procurement in Malaysia is highly centralized, with the MOH serving as the dominant institutional buyer for health products across government hospitals, health clinics, and public health programs. Federal-level procurement is managed primarily through Pharmaniaga Logistics Sdn Bhd, a government-linked concession company responsible for the storage and distribution of pharmaceuticals and medical supplies to MOH facilities under a long-standing concession agreement. Large-scale and high-value tenders are coordinated by the MOH Procurement Division in conjunction with the Ministry of Finance and the Government Procurement Division (Bahagian Perolehan Kerajaan), with awards published through the MyProcurement portal. National tenders for pharmaceutical products are typically issued on a two-year or three-year cycle, with pricing negotiations conducted centrally and contracts awarded to registered suppliers meeting technical and financial criteria. State health departments retain limited procurement authority for localized or emergency purchases, but strategic and bulk commodity procurement remains a federal function. The MOH Drug Formulary (Formulary Ubat) and the Medical Device Formulary serve as the reference lists governing which products are eligible for public procurement, making formulary listing a critical market access milestone for suppliers.

The private healthcare sector in Malaysia is substantial and growing, comprising private hospitals, specialist clinics, retail pharmacies, and diagnostic laboratories that procure health products independently through commercial distributors, wholesalers, and direct manufacturer agreements without centralized tender requirements. Private procurement is demand-driven and price-sensitive, with group purchasing arrangements emerging among larger private hospital networks. Malaysia is an upper-middle-income country and does not generally access donor-funded procurement mechanisms such as those administered by UNICEF Supply Division, the Global Fund, Gavi, or USAID for mainstream health commodities; however, selective engagement with international agencies occurs in the context of specific public health programs, outbreak preparedness, and regional health security initiatives. The Malaysian government has implemented local manufacturing preference policies to stimulate domestic pharmaceutical and medical device production, including preferential pricing margins of up to 10 percent for locally manufactured products in public tenders and incentives administered by the Malaysian Investment Development Authority (MIDA) for manufacturers establishing production facilities in-country. Halal certification, issued by the Department of Islamic Development Malaysia (JAKIM), is an increasingly important market consideration, particularly for pharmaceuticals and consumables intended for the Muslim population and for products targeting export to OIC member states through Malaysia as a hub.